Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth 2024-03-21 22:44
Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization 2022-08-26 22:09
Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration 2022-06-23 12:19
Ocumension Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength 2021-08-25 12:35
Ocumension Therapeutics Announces 2021 Interim Results 2021-08-21 00:19
Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding 2021-03-20 18:20
Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases 2020-10-30 10:54
Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange 2020-07-10 21:55
1